Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2016
Pharma News, 2016
AZ hands off gout drug Zurampic to Ironwood for $100M-plus
LesinuradDid Ironwood Pharmaceuticals just pick up a promising product, or did AstraZeneca just unload a problematic one? You be the judge.
DuPont expects SEC review of Dow deal to end by June 30
DuPont said on Tuesday it expected the U.
Alexion mulls producing pipeline drugs in Ireland
A senior executive with Alexion ($ALXN), the maker of orphan drug Soliris, said the company is taking a hard look at locating facilities to produce its new pipeline of drugs in Ireland.
Chinese Scientists Modify Gene To Make Humans Immune To HIV Infection
BEIJING.
TECFIDERA® data highlights benefit of early treatment in relapsing-remitting multiple sclerosis
Biogen present new TECFIDERA (dimethyl fumarate) research at the 68thannual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada.
Study identifies compound that reverses symptoms of Alzheimer's, Parkinson's
Alzheimer's and Parkinson's disease are the two most common neurodegenerative disorders worldwide and cause untold suffering to millions of patients and their families.
Drug to combat often-fatal blood poisoning 'could save millions of lives a year'
A new drug for sepsis has been developed by scientists that could save the lives of millions of people a year.
Taking aspirin could increase cancer survival by 20 percent
Patients receiving cancer treatment could increase their chance of survival by up to 20% and help stop their cancer from spreading by taking a low-dose of aspirin, new research suggests.
FDA Grants Orphan Drug Exclusivity to EVOMELA™ (melphalan) for Injection, Indicated for Multiple Myeloma
HENDERSON, Nev.
AstraZeneca slips on talk of possible £7bn bid for US cancer specialist
AstraZeneca has slipped back following weekend reports it was considering a £7bn bid for San Francisco cancer treatment specialist Medivation.
Theranos director: Treatment of CEO Holmes 'unfair'
Dick Kovacevich, the former Wells Fargo CEO and current Theranos board member, defended the embattled lab testing start-up's boss Elizabeth Holmes on Wednesday.
Shire building $400M biologics plant, adding 400 jobs in Ireland
Rare disease drug specialist Shire ($SHPG) has been on a buying streak lately, culminating with its $32 billion deal for Baxalta ($BXLT).
38
39
40
41
42
43
44
45
46
